Cancer treatment and Improving quality of life of cancer patients by ADP-Ribose regulatory platform technology
PearlsInMires is an oncology drug development company with an ADP-Ribose regulatory platform.
Our team is dedicated to the discovery and R&D of anticancer drugs for the treatment of cancer patients.
We are advancing First-In-Class technologies with a primary focus on ADP-Ribose regulation, a new class of precision medicine targets.
We are promoting the development of innovative anticancer drugs by securing mechanisms of
"synthetic lethality intervention", "epigenetic control", and "gene regulation"
through ADP-Ribose regulatory platform.
Inducing cancer cell death mechanism through ADP-Ribose regulatory platform technology.
We have established the First-In-Class platform with ADP-Ribose regulatory technology.
We are considering the unique robustness and preservation of the cancer cells that are clearly distinct from normal cells
and achieving low-toxic/high-efficient conditions that breaks away from the stereotype of existing inhibitory anti-cancer drugs.
Pipeline from ADP-Ribose regulatory platform
We are actively promoting R&D using the ADP-Ribose regulatory platform technology targeting various solid cancers.
Our ADP-Ribose regulatory platform technology has great potential to replace or complement the existing cancer therapies.
- Targets of our technologies:
- Treatment of all solid cancers with increased target expression
- Overcoming resistance to existing PARP inhibitors
- Overcoming resistance to existing Immunotherapies
- Overcoming resistance to standard therapies using chemo/targeted therapies
- Inducing synergistic effect with all existing anticancer drugs
Notice of technology
Notice related to technology development of PearlsInMires.
Company business announcement of PearlsInMires.